1,916 material Form 8-K filings that 1,609 companies we cover made with the SEC in July 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Sunbelt Rentals Holdings completed the sale of $450 million of 4.950% senior notes due 2030 and $750 million of 5.650% senior notes due 2036 on July 14, 2026. The notes add $1.2 billion of long-term debt, with interest payable semi-annually starting February 12, 2027, and rank equal with the company's existing and future senior debt.
2030 Notes: $450 million at 4.950%, issued at 99.627%, maturing August 12, 2030
2036 Notes: $750 million at 5.650%, issued at 99.048%, maturing August 12, 2036
Holders may require repurchase at 101% of principal plus accrued interest upon a change in control triggering event
Notes are jointly and severally guaranteed by domestic subsidiaries that guarantee the revolving credit facility; BNY Mellon serves as trustee
Viking Acquisition Corp. II, a blank check company, said holders of its public units may elect to separately trade the Class A ordinary shares and warrants starting July 20, 2026. The change is administrative, and the filing does not report any financial results or business developments.
Unit holders can separate units from July 20, 2026 by having their brokers contact Continental Stock Transfer & Trust Company.
Each unit consists of one Class A ordinary share and one-third of one redeemable warrant; no fractional warrants will be issued on separation.
Unseparated units keep trading as VII U. The 8-K body gives VAII for the Class A shares, while Exhibit 99.1 gives VII; both list the warrants as VII WS on the NYSE.
SBC Medical received a Nasdaq notice that it no longer meets independent director and audit committee rules after Mike Sayama chose not to seek re-election. Stockholders also approved charter amendments and the board adopted amended bylaws, including a majority-vote resignation policy for uncontested director elections. The company says the notice has no immediate effect on its listing, but it must restore compliance within the cure period.
Nasdaq notice received July 10, 2026; board has four members, two of them independent, and the audit committee has two independent directors
Cure period ends at the earlier of the next annual meeting or July 9, 2027, or January 5, 2027 if the next annual meeting is held before that date
Restated charter effective July 9, 2026; amended and restated bylaws adopted July 8, 2026
Stockholders elected four directors and ratified MaloneBailey, LLP as auditor for fiscal 2026 with 93,954,650 votes for
Anika Therapeutics entered into a Fifth Amendment to its revolving credit agreement with Bank of America, N.A., extending the senior revolving line of credit to a $50.0 million facility maturing July 10, 2031. The company may request up to an additional $50.0 million in commitments, for a maximum of $100.0 million, subject to lender approval. The filing does not report any borrowings under the facility, and the amendment adds lender liens on substantially all assets and financial covenants that shareholders should note.
Senior revolving line of credit of $50.0 million, maturing July 10, 2031, with an option for up to $100.0 million aggregate commitments
Interest at SOFR plus 0.25% to 1.25%, based on the consolidated leverage ratio; commitment fee of 0.20% to 0.30% per annum on unused amounts
Lenders have a first priority lien on substantially all assets, except certain intangible assets; covenants cover leverage and interest coverage ratios
Amendment dated July 10, 2026; 8-K filed July 14, 2026 with Exhibit 10.1 attached
Research Alliance Corporation IV, a blank check company focused on healthcare, closed its initial public offering on July 14, 2026, selling 7,500,000 Class A ordinary shares at $10.00 each for $75 million in gross proceeds. The IPO and a $2.75 million private placement to the sponsor funded a trust account of $75 million for public shareholders. The filing says the company must complete an initial business combination within 24 months of the IPO closing, or liquidate.
Closed IPO of 7,500,000 Class A ordinary shares at $10.00 per share on July 14, 2026, for gross proceeds of $75,000,000 before underwriting discounts and offering expenses.
Sponsor Research Alliance Holdings IV LLC bought 275,000 private placement shares at $10.00 each, for total proceeds of $2,750,000.
$75,000,000 of net proceeds and private placement funds, including a $2,250,000 underwriter deferred commission, were deposited in a trust account with Continental Stock Transfer & Trust Company as trustee.
Alan Musso and John Maslowski were appointed to the board on July 10, 2026, and each received 30,000 Class B ordinary shares from the sponsor as compensation.
enVVeno Medical Corporation issued an investor presentation on July 14, 2026, which it may use with investors, analysts and others. The filing states the presentation is attached as Exhibit 99.1 but does not summarize its contents, so the filing itself reports no new financial results, guidance or deal terms.
Investor presentation issued July 14, 2026, attached as Exhibit 99.1
Company may use the presentation at investor, analyst and other meetings, in whole or in part
Filing contains no financial figures, guidance or transaction terms in its text
Churchill Capital Corp XII, a blank-check SPAC, appointed Paul Lapping as a director on July 13, 2026, and as chairperson of its Audit Committee, replacing interim chair William Sherman, who remains on the committee. The company also agreed to pay each of Mr. Sherman and Mr. Lapping $75,000 per year in cash compensation starting August 1, 2026.
Paul Lapping appointed director effective July 13, 2026, and named Audit Committee chairperson, replacing William Sherman as interim chair
Board compensation of $75,000 per annum in cash for each of William Sherman and Paul Lapping, beginning August 1, 2026
Mr. Lapping signed a joinder to an April 27, 2026 letter agreement requiring redemption rights waivers and votes in favor of an initial business combination
Allstate said Christian Lown will become Executive Vice President and Chief Financial Officer on August 3, 2026, succeeding Jess Merten, who became President of Property-Liability in October 2025. John Dugenske has served as interim CFO and will continue in that role until Lown starts. The filing sets Lown's pay package, including a $875,000 base salary and a $2,000,000 sign-on bonus, which matters to shareholders as a senior finance leadership change.
Christian Lown starts as EVP and CFO effective August 3, 2026, reporting to Chair, President and CEO Tom Wilson.
Lown's prior roles include CFO of CoStar Group (July 2024 to July 2026) and CFO of Freddie Mac (June 2020 to June 2024).
Compensation: $875,000 annual base salary, annual target cash incentive of 200% of salary, and equity incentive of 375% of salary.
Sign-on package: $2,000,000 one-time cash bonus and $4,100,000 in RSUs vesting ratably over three years.
AutoZone completed the sale of $850 million in aggregate principal of 4.950% senior notes maturing July 15, 2031, on July 14, 2026. The notes are senior unsecured debt, so the company takes on new borrowing that must be repaid with interest.
Principal amount of $850 million; fixed interest rate of 4.950% per year, paid semi-annually on January 15 and July 15, starting January 15, 2027
Notes mature July 15, 2031 and rank equally with the company's other senior unsecured liabilities
Issued under an August 8, 2003 indenture with Regions Bank as successor trustee, and sold under a shelf registration filed July 7, 2026
Company may redeem the notes early, and holders may require repurchase after a change of control triggering event
Disciplined Growth Acquisition Corporation said that starting July 17, 2026, holders of its IPO units may separately trade the Class A ordinary shares and the rights included in those units. The change is administrative and does not alter the terms of the shares or rights, which remain tied to a future initial business combination.
Separate trading begins July 17, 2026, on the New York Stock Exchange.
Each unit holds one Class A ordinary share and one right to receive one-fourth of a Class A ordinary share upon completion of an initial business combination.
Only whole rights will trade; no fractional rights will be issued on separation.
Units not separated continue to trade as DGACU; separated shares and rights trade as DGAC and DGACR.
Equinix said Chief Business Officer Jon Lin will separate from the company effective July 18, 2026, and that he will receive severance payments and benefits under the Executive Severance Plan, subject to a release of claims. The company has spread his responsibilities across its existing senior leadership and expects to announce a new Chief Product Officer soon.
Jon Lin, Chief Business Officer, separates from Equinix effective July 18, 2026
Severance payments and benefits under the Executive Severance Plan, subject to a release of claims
Responsibilities distributed across existing senior leadership team under a transition plan
New Chief Product Officer announcement expected in the near future
Ulta Beauty said board member Kelly Garcia will become its Chief Technology Officer effective August 31, 2026, and will resign from the board on that date. The change moves a board member into a senior executive role and is a leadership change rather than a financial result.
Kelly Garcia, a board member since 2022, is appointed Chief Technology Officer effective August 31, 2026.
Garcia resigns from the Board of Directors effective on his CTO start date.
Garcia previously served as Executive Vice President and CTO of Domino's Pizza since July 2012.
The filing contains no financial results or guidance.
On July 13, 2026, AMREP awarded CEO Christopher V. Vitale and CFO Adrienne M. Uleau cash bonuses and restricted stock under its 2016 Equity Compensation Plan, and approved salary increases effective July 27, 2026. The awards are compensation actions for executives and do not involve a change in officers or a financial result.
Vitale: $178,000 cash bonus and 8,700 restricted shares, vesting in 2,900-share tranches on July 13 of 2027, 2028 and 2029
Uleau: $64,000 cash bonus and 2,250 restricted shares, vesting in 750-share tranches on July 13 of 2027, 2028 and 2029
Salaries set to $395,000 for Vitale and $205,000 for Uleau, effective July 27, 2026
West Pharmaceutical Services entered into an amended and restated crosslicense agreement and two distributorship agreements with Daikyo Seiko, effective July 14, 2026, which the company says are substantially similar to the 2017 agreements as amended in 2018 and 2019. West holds a 49% ownership interest in Daikyo, and the filing describes the agreements as sharing know-how and granting licenses for pharmaceutical packaging and delivery components, with each agreement running 10 years.
Agreements are effective July 14, 2026 and each has a 10-year term
West is the exclusive distributor of Daikyo products outside Japan, subject to limited exceptions
Daikyo is a non-exclusive distributor of West products in Japan
Full agreement texts will be filed as redacted exhibits to the 10-Q for the quarter ending September 30, 2026
Sezzle Inc. said it will release its second quarter 2026 results after the market close on August 6, 2026, and hold a conference call at 5:00 p.m. ET that day. The filing contains no financial results, so it does not yet show revenue, profit, or guidance for the quarter.
Second quarter 2026 results release: August 6, 2026, after market close
Conference call and webcast: 5:00 p.m. ET on August 6, 2026
Management will present at four investor conferences between August 13 and September 17, 2026
PVH Corp. said its Employment Agreement with Alexis Rollier, currently Global Chief Operating Officer and Global Chief Financial Officer at Sephora, makes him CFO. He joins in early September 2026 and replaces Melissa Stone, who has served as interim CFO since January 1, 2026. The filing sets his base salary at $850,000 and details equity and severance terms, which matter to shareholders as they define the cost and terms of the company's new finance leader.
Alexis Rollier, age 57, will join PVH as CFO in early September 2026, succeeding interim CFO Melissa Stone through September 7, 2026.
Initial base salary is $850,000, with a target bonus of 100% of base salary and a 2027 equity grant of about $1,150,000 in PSUs plus about $1,150,000 in RSUs.
A $375,000 make-whole cash advance and a make-whole RSU award with a grant date value of $275,000 replace awards he forfeits at his current employer.
Severance is two times base salary plus target bonus if terminated without cause or for good reason, with higher protection within two years after a change in control.
The Procter & Gamble Company declared a quarterly dividend of $1.0885 per share on its common stock and its Series A and Series B ESOP Convertible Class A Preferred Stock. Common shareowners of record at the close of business on July 24, 2026 will receive the payment, which is due on or after August 17, 2026. The release states P&G has paid a dividend for 136 consecutive years and has increased it for 70 consecutive years.
Quarterly dividend of $1.0885 per share on common and ESOP preferred stock
Common stock record date is July 24, 2026; payment on or after August 17, 2026
Company states it has increased its dividend for 70 consecutive years and paid one for 136 consecutive years
Domino's Pizza appointed Michael C. Creedon, Jr. and Anneliese Olson to its board, effective July 15, 2026, expanding the board from eight to ten directors. The board also named Corie S. Barry lead independent director, replacing Richard L. Federico, who stays on the board as Audit Committee chairman. The filing also discloses that Chief Technology and Data Officer Kelly E. Garcia will resign effective August 28, 2026, and the company has started a search for a successor.
Michael C. Creedon, Jr. (Dollar Tree CEO) and Anneliese Olson (HP Inc. President, Imaging, Printing and Solutions) join the board effective July 15, 2026, and both join the Audit Committee
Corie S. Barry, a director since July 2018, replaces Richard L. Federico as Lead Independent Director
Executive Vice President and Chief Technology and Data Officer Kelly E. Garcia resigns effective August 28, 2026, to accept another executive position outside the company
Paramount Gold Nevada filed a technical report summary for its Grassy Mountain Gold Project in Oregon, prepared under subpart 1300 of Regulation S-K, along with consents from five qualified persons. The filing is administrative and contains no financial results, guidance, or transaction terms, so it gives shareholders no new financial figures.
Technical report summary filed July 14, 2026; Item 8.01 gives an effective date of May 27, 2026, while the exhibit index lists May 26, 2026
Consents filed from Ausenco Engineering Canada Inc., RESPEC Company LLC, WSP USA Inc., Geotechnical Mine Solutions, and SLR International Corporation
Report signed by CEO Rachel Goldman on July 14, 2026
PagerDuty appointed Alex Shootman, CEO of Alkami Technology, to its board of directors on July 14, 2026, filling the seat vacated by Elena Gomez, who resigned from the board and its audit committee effective July 11, 2026. The company said Gomez's resignation was not due to any disagreement on operations, policies, or practices. The change is a board governance update that does not alter reported financial results.
Alex Shootman appointed as a Class I director, term expiring at the 2029 Annual Meeting of Stockholders, effective July 14, 2026
Shootman also joins the Audit Committee and the Compensation Committee, effective July 14, 2026
Elena Gomez resigned from the board and audit committee effective July 11, 2026, with no disagreement cited
Shootman's compensation begins July 14, 2026, under the non-employee director compensation policy
Willamette Valley Vineyards appointed Christopher Riccardi and Greg Voorhies as directors effective July 11, 2026. Both are in Class III with terms ending at the 2028 annual meeting, and they will receive compensation under the company's board compensation plan.
Christopher Riccardi and Greg Voorhies appointed to the board effective July 11, 2026
Both are members of directors group III, with terms expiring at the 2028 annual meeting of shareholders
Compensation follows the WVV Board Member Compensation Plan, as described in the May 28, 2026 proxy statement
The filing states no arrangements tied to their appointment and no related-party transactions requiring disclosure
Redwire Corp's board appointed Gregory L. Heston as a director effective July 10, 2026, filling the seat left by David Kornblatt's previously announced resignation. Heston also joined the Audit Committee and was determined to be independent under NYSE and Rule 10A-3 standards, adding a former EY audit partner to oversight of financial reporting.
Gregory L. Heston appointed to the board effective July 10, 2026, filling the vacancy from David Kornblatt's resignation
Heston is a Class III director with a term expiring at the 2027 Annual Meeting of Shareholders
Heston joined the Audit Committee; he is a retired EY audit partner with 38 years of public accounting experience
Heston and the Company entered into an Indemnification Agreement; he will be paid under the non-employee director compensation policy
Fortrea Holdings said Chief Accounting Officer Robert Parks will resign effective August 7, 2026, to pursue an opportunity outside the contract research industry, and that Vice President of Accounting Carrie Russell will serve as interim principal accounting officer. The filing also details the transition of CFO Jill McConnell, who will remain employed through September 8, 2026, with severance of $1,017,500 if she stays through that date. The company states Parks' decision was not the result of any disagreement over operations, policies, or accounting practices.
Robert A. Parks informed the company on July 8, 2026, of his resignation as Chief Accounting Officer and principal accounting officer, effective August 7, 2026.
Carrie Russell, Vice President of Accounting since August 2024, becomes interim principal accounting officer and interim Chief Accounting Officer, receiving a one-time $20,000 bonus plus $10,000 per month.
CFO Jill McConnell stays through September 8, 2026, with severance of $1,017,500 paid in two installments of $508,750, and a consulting agreement runs through March 8, 2027.
Repay Holdings agreed on July 13, 2026 to a cooperation agreement with PCP Managers II, L.P., an affiliate of one of its largest stockholders, and expanded its board from six to seven members. Zachary F. Sadek, a Senior Partner at Parthenon Capital Partners, was appointed to the board effective July 13, 2026, and the company agreed to nominate him for election at its 2027 annual meeting. The filing contains no financial results, so the change is a governance development rather than a measure of business performance.
Board size increased from six to seven members; Zachary F. Sadek appointed effective July 13, 2026.
Sadek's initial term expires at the 2027 annual meeting; the company agreed to nominate him for election there.
The agreement includes customary standstill and confidentiality terms that remain in effect until the earlier of 30 days after Sadek leaves the board or the first day after the 2027 annual meeting concludes.
The company says six of seven directors now qualify as independent under NASDAQ guidelines.
Effective July 8, 2026, Annie Van Broekhoven retired and stepped down from Propanc Biopharma's Board of Directors, and the Board appointed Carlo Campiciano to fill the vacancy. The filing describes Mr. Campiciano as a qualified accountant with prior experience as CFO and Company Secretary of MedAdvisor Limited, an ASX-listed company. The change is a board composition update and the filing does not report any financial results.
Annie Van Broekhoven retired and resigned from the Board effective July 8, 2026
Carlo Campiciano appointed to the Board the same day to serve until resignation or removal
Mr. Campiciano was CFO and Company Secretary of MedAdvisor Limited, an ASX-listed company
Director Agreement dated July 8, 2026 with Mr. Campiciano filed as Exhibit 10.1
Ligand Pharmaceuticals completed its merger with XOMA Royalty on July 14, 2026, paying $39.00 per share in cash plus one contingent value right (CVR) per share, for a total equity value of approximately $739 million. In connection with the closing, Ligand entered an amended credit agreement providing a $125.0 million revolving credit facility maturing September 12, 2028. Ligand expects the deal to be immediately accretive, but CVR holders may receive no payment, depending on the outcome of pending litigation at XOMA Royalty.
Consideration: $39.00 per XOMA Royalty share in cash plus one CVR per share, with total equity value of approximately $739 million
Ligand expects the deal to add approximately $0.50 per share to projected 2026 adjusted EPS and $1.50 per share to projected 2027 adjusted EPS
Amended Credit Agreement provides a $125.0 million revolving credit facility maturing September 12, 2028, secured by certain collateral and guaranteed by material domestic subsidiaries
Ligand will provide an updated 5-year outlook at its Investor Day on December 8, 2026
First Bancorp (Nasdaq: FBNC) signed a merger agreement to acquire First Carolina Bancshares Corporation, parent of Carolina Bank & Trust of Florence, South Carolina, in a deal with an aggregate value of $166 million. The filing says the deal is expected to close in the fourth quarter of 2026 or early in the first quarter of 2027, subject to First Carolina shareholder approval and regulatory approvals, and that the companies expect First Bancorp's quarterly earnings release on July 22, 2026 to be in line with market expectations.
Consideration to First Carolina shareholders: 14.5340 First Bancorp shares plus $294.94 in cash per First Carolina share, based on First Bancorp's $64.22 share price as of July 13, 2026
Total consideration includes 1,967,017 First Bancorp shares and $40 million in cash
Carolina Bank & Trust had approximately $831 million in assets, according to the press release
Under certain circumstances, First Carolina may owe First Bancorp a $6.4 million termination fee; the agreement can be terminated if the merger is not completed by June 30, 2027
Syndax Pharmaceuticals held an R&D event on July 14, 2026, and disclosed two pipeline additions: SNDX-4321, an externally licensed EGFR inhibitor for non-small cell lung cancer, and SNDX-62122, a next-generation menin inhibitor selected for myelofibrosis. The filing furnishes the press release and presentation but gives no new financial results, and it sets out development timelines, including a Phase 2 axatilimab trial in IPF with topline data expected in 4Q26.
SNDX-4321: IND submission expected by end of 2026 and Phase 1 trial in EGFR-mutated NSCLC planned for 2027; Syndax holds an exclusive worldwide license.
SNDX-62122 is the first candidate from Syndax's wholly owned next-generation menin inhibitor library; a revumenib Phase 1/2 proof-of-principle trial in myelofibrosis is expected to start in 4Q26.
Phase 2 trial of axatilimab in IPF remains on track for topline data in 4Q26.
Presentation states Revuforj and Niktimvo were each annualizing at about $200 million as of 1Q26.
Diodes Incorporated agreed on July 10, 2026, to acquire ElevATE Semiconductor, a San Diego fabless chip designer for automated test equipment, through a merger. The base price is $250.0 million in cash, subject to adjustments, plus up to $50.0 million in earnout payments tied to 2027 through 2030 revenue and gross margin targets. The deal is subject to closing conditions including HSR Act clearance and is expected to close in the second half of 2026.
Base purchase price of $250.0 million in cash, subject to customary adjustments for cash, debt, transaction costs, taxes and working capital
Earnout of up to $50.0 million based on post-closing revenue and gross margin thresholds for calendar years 2027 through 2030
Diodes expects ElevATE to add approximately $50 million of revenue in the first twelve months after closing
Expected close in the second half of 2026, subject to regulatory approvals including the HSR Act waiting period
Bread Financial said Chief Commercial Officer Valerie Greer will retire on or around February 19, 2027, and that Dennis McCarthy will be promoted to Executive Vice President and Chief Revenue Officer in early September. Greer's retirement agreement provides a $945,000 cash payment and continued salary until her retirement date, and no new equity grants.
Valerie Greer, EVP and Chief Commercial Officer, will retire on or around February 19, 2027, and remain with the company through February 2027 for transition.
Retirement agreement dated July 8, 2026 includes a $945,000 cash payment, payable within 30 days of the retirement date, and her full-year 2026 annual cash incentive award.
Dennis McCarthy, who joined in 2021, becomes EVP and Chief Revenue Officer in early September, reporting to CEO Ralph Andretta.
Alto Neuroscience entered into an underwriting agreement on July 13, 2026, to sell 3,776,436 shares of common stock at $26.48 per share in a registered direct offering, with estimated net proceeds of approximately $93.9 million. The company plans to use the proceeds with its existing cash to accelerate ALTO-207 development, including an additional planned Phase 3 trial in treatment-resistant depression. The sale adds new shares outstanding, which dilutes existing holders, and closing is expected July 14, 2026.
Shares offered: 3,776,436 common shares at $26.48 each
Estimated net proceeds: approximately $93.9 million, after underwriting discounts and offering expenses
Use of proceeds: ALTO-207 clinical development, including an additional Phase 3 trial in treatment-resistant depression, and general working capital
Expected closing: July 14, 2026, subject to customary conditions; BofA Securities is representative
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.